VFY.ASX: Vitrafy Placement Completion and SPP Announcement

Vitrafy Placement Completion and SPP Announcement

Stock	VFY.ASX (VFY.ASX)
Release Time	12 Jun 2026, 9:32 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Vitrafy Completes A$30M Placement and Announces SPP

Key Points

A$30M institutional placement completed at A$2.60 per share
SPP offer to raise up to A$2M for eligible shareholders
Funds to accelerate US operations and Guardion manufacturing
Placement supported by new and existing institutional investors

Full Summary

Vitrafy Life Sciences Limited has successfully completed a A$30 million institutional placement, receiving firm commitments at a price of A$2.60 per share. The placement was strongly supported by new and existing institutional and sophisticated investors, reflecting confidence in the company's progress in the US blood market. Additionally, Vitrafy will offer a Share Purchase Plan (SPP) to eligible shareholders in Australia and New Zealand to raise up to A$2 million. Proceeds from the placement and SPP will fund the manufacturing of Guardion devices to meet anticipated demand, accelerate US operations, and support general working capital. The SPP will be open for applications from shareholders registered in Australia or New Zealand on the record date, with the offer closing on July 3, 2026.

Guidance

A$30M raised through placement; SPP to raise up to A$2M

Outlook

Vitrafy plans to use the funds to scale Guardion manufacturing, accelerate US operations, and support working capital. The company is confident in its growth opportunities in the US blood market.